Withdrawal Assessment report for Jenzyl, INN: RIDAFOROLIMUS
ثبت نشده
چکیده
This withdrawal Assessment Report is based on the latest assessment report adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with the “Questions and Answers” document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application.
منابع مشابه
SINEREM, INN: superparamagnetic iron oxide nanoparticles stabilised with dextran and sodium citrate
International Nonproprietary Name (INN): superparamagnetic iron oxide nanoparticles stabilised with dextran and sodium citrate Day 180 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with the " Question and Answer " document on the withdrawal of the application: the Assessment Report may not include ...
متن کاملA phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
PURPOSE Ridaforolimus is an investigational, potent, selective mTOR inhibitor. This study was conducted to determine the recommended phase 2 dose (RP2D), maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors. EXPERIMENTAL DESIGN In this phase 1, multicenter, open-label study in children aged 6 to <18 years with ad...
متن کاملPharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat
The rapamycin analog, ridaforolimus, has demonstrated potent anti-proliferative effects in cancer treatment, and it currently is being evaluated in a range of clinical cancer studies. Ridaforolimus is an extremely lipophilic compound with limited aqueous solubility, which may benefit from formulation with polymeric micelles. Herein, we report the encapsulation of ridaforolimus in 1,2-distearoyl...
متن کاملA Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
PURPOSE The PI3K/Akt/mTOR signaling pathway is aberrantly activated in many cancers. Combining ridaforolimus, an mTOR inhibitor, with MK-2206, an Akt inhibitor, may more completely block the PI3K pathway and inhibit tumor growth. EXPERIMENTAL DESIGN This phase I study assessed dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of oral ridaforolimus plus oral M...
متن کاملCancer Therapy: Clinical A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Purpose: The PI3K/Akt/mTOR signaling pathway is aberrantly activated in many cancers. Combining ridaforolimus, an mTOR inhibitor, with MK-2206, an Akt inhibitor, may more completely block the PI3K pathway and inhibit tumor growth. Experimental Design: This phase I study assessed dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of oral ridaforolimus plus oral M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013